within Pharmacolibrary.Drugs.ATC.L;

model L04AG05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.159 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.00484,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin, thereby blocking the interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1). It is approved for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults, acting as a gut-selective anti-inflammatory agent.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters for vedolizumab in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.</p><h4>References</h4><ol><li><p>Feagan, BG, et al., &amp; Parikh, A (2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>The New England journal of medicine</i> 369(8) 699–710. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1215734&quot;>10.1056/NEJMoa1215734</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23964932/&quot;>https://pubmed.ncbi.nlm.nih.gov/23964932</a></p></li><li><p>Sandborn, WJ, et al., &amp; Vermeire, S (2020). Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> 158(3) 562–572.e12. DOI:<a href=&quot;https://doi.org/10.1053/j.gastro.2019.08.027&quot;>10.1053/j.gastro.2019.08.027</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31470005/&quot;>https://pubmed.ncbi.nlm.nih.gov/31470005</a></p></li><li><p>Hyams, JS, et al., &amp; Lirio, RA (2022). Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn&#x27;s Disease: Results from the Phase 2 HUBBLE Study. <i>Journal of Crohn&#x27;s &amp; colitis</i> 16(8) 1243–1254. DOI:<a href=&quot;https://doi.org/10.1093/ecco-jcc/jjac036&quot;>10.1093/ecco-jcc/jjac036</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35301512/&quot;>https://pubmed.ncbi.nlm.nih.gov/35301512</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AG05;
